| Serial Number | 79253207 |
| Word Mark | XBRANE |
| Filing Date | Monday, November 12, 2018 |
| Status | 707 - PARTIAL SECTION 71 ACCEPTED |
| Status Date | Saturday, February 21, 2026 |
| Registration Number | 6004520 |
| Registration Date | Tuesday, March 10, 2020 |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, December 24, 2019 |
| Goods and Services | [ Surgical apparatus and instruments; injection device for pharmaceuticals; injection syringes; injection needles; medical apparatus, namely, automatic infusion and injection devices for administering drugs to humans ] |
| Goods and Services | Scientific and medical research and development; pharmaceutical research and development services; research and development services in the fields of biological similar pharmaceuticals, generic drugs, biotechnology, diagnostics and pharmaceuticals; consultancy services relating to the discovery and evaluation of drugs and chemical compounds having diagnostic properties and therapeutic properties; technical support services, namely, troubleshooting in the nature of diagnosing problems with medical equipment; diagnostic services in the field of troubleshooting biotechnology and pharmaceutical equipment for scientific research purposes; analyzing biotechnology and pharmaceutical equipment for scientific research purposes; development of new technology for others in the field of biotechnology; medical, pharmaceutical and biotechnological laboratory research services; information, consultancy and advisory services relating to scientific and medical research and development, biotechnological and pharmaceutical research and development and medical equipment research and development |
| Indication of Colors claimed | The color(s) dark blue and light blue is/are claimed as a feature of the mark. |
| Goods and Services | [ Pharmaceutical preparations and medical preparations all for treating cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions, infectious diseases, ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis, bone metastasis; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions and infectious diseases; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis, bone metastasis; chemotherapeutics; hormones for medical purposes; pharmaceutical agents for treating metabolic disorders; amino acids for medical purposes; pharmaceutical agents for treating immunity disorders; pharmaceutical agents for treating physically caused lesions; antiviral preparations; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosis, treatment and prevention of cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions, infectious diseases; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosis, treatment and prevention of ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis and bone metastasis ] |
| Description of Mark | The mark consists of the stylized light blue and dark blue wording "XBRANE". |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | G - NOT AVAILABLE |
| Class Status Date | Saturday, February 21, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | G - NOT AVAILABLE |
| Class Status Date | Saturday, February 21, 2026 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, March 5, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Xbrane Biopharma AB |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 09 - Joint Stock Company |
| Address | SOLNA SE-171 48 SE |
| Party Name | Xbrane Biopharma AB |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 09 - Joint Stock Company |
| Address | SE |
| Party Name | Xbrane Biopharma AB |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 09 - Joint Stock Company |
| Address | SE |
| Event Date | Event Description |
| Thursday, February 28, 2019 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Tuesday, March 5, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, March 5, 2019 | ASSIGNED TO EXAMINER |
| Thursday, March 7, 2019 | NON-FINAL ACTION WRITTEN |
| Friday, March 8, 2019 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, March 9, 2019 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, March 20, 2019 | REFUSAL PROCESSED BY MPU |
| Wednesday, March 20, 2019 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, April 6, 2019 | REFUSAL PROCESSED BY IB |
| Wednesday, June 12, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, June 12, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 12, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, July 9, 2019 | FINAL REFUSAL WRITTEN |
| Tuesday, July 9, 2019 | FINAL REFUSAL E-MAILED |
| Tuesday, July 9, 2019 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, November 7, 2019 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Thursday, November 7, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, November 7, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, November 15, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, November 19, 2019 | ASSIGNED TO LIE |
| Wednesday, December 4, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, December 18, 2019 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, December 18, 2019 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Tuesday, December 24, 2019 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 24, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Friday, January 3, 2020 | NOTIFICATION PROCESSED BY IB |
| Tuesday, March 10, 2020 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, June 10, 2020 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Saturday, July 11, 2020 | FINAL DISPOSITION PROCESSED |
| Saturday, July 11, 2020 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, July 31, 2020 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Monday, March 10, 2025 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Friday, October 3, 2025 | TEAS SECTION 71 RECEIVED |
| Monday, February 9, 2026 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Saturday, February 21, 2026 | REGISTERED - PARTIAL SEC 71 ACCEPTED |
| Saturday, February 21, 2026 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED |